Send to

Choose Destination
Tissue Eng Part B Rev. 2015 Dec;21(6):560-71. doi: 10.1089/ten.TEB.2015.0068. Epub 2015 Aug 27.

Turning Regenerative Medicine Breakthrough Ideas and Innovations into Commercial Products.

Author information

1 Medtronic-Sofradim Production , Trévoux, France .
2 London Business School , London, United Kingdom .
3 NxR Biotechnologies GmbH , Basel, Switzerland.
4 College of Pharmacy UNT Health Science Center , Fort Worth, Texas.
5 London Regenerative Medicine Network , London, United Kingdom .
6 Advanced Centre for Biochemical Engineering, University College London , London, United Kingdom .
7 ReNeuron Ltd. , Guildford, United Kingdom .
8 Institute of Experimental and Clinical Research , Université catholique de Louvain and Cliniques St-Luc, Brussels, Belgium .
9 PROMETHERA Biosciences, Mont-St.-Guibert, Belgium .
10 CellCoTec, Bilthoven, The Netherlands .
11 Juventas Therapeutics, Inc. , Cleveland, Ohio.
12 Holostem Terapie Avanzate, Srl, Modena, Italy .


The TERMIS-Europe (EU) Industry committee intended to address the two main critical issues in the clinical/commercial translation of Advanced Therapeutic Medicine Products (ATMP): (1) entrepreneurial exploitation of breakthrough ideas and innovations, and (2) regulatory market approval. Since January 2012, more than 12,000 publications related to regenerative medicine and tissue engineering have been accepted for publications, reflecting the intense academic research activity in this field. The TERMIS-EU 2014 Industry Symposium provided a reflection on the management of innovation and technological breakthroughs in biotechnology first proposed to contextualize the key development milestones and constraints of allocation of financial resources, in the development life-cycle of radical innovation projects. This was illustrated with the biofuels story, sharing similarities with regenerative medicine. The transition was then ensured by an overview of the key identified challenges facing the commercialization of cell therapy products as ATMP examples. Real cases and testimonies were then provided by a palette of medical technologies and regenerative medicine companies from their commercial development of cell and gene therapy products. Although the commercial development of ATMP is still at the proof-of-concept stage due to technology risks, changing policies, changing markets, and management changes, the sector is highly dynamic with a number of explored therapeutic approaches, developed by using a large diversity of business models, both proposed by the experience, pitfalls, and successes of regenerative medicine pioneers, and adapted to the constraint resource allocation and environment in radical innovation projects.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center